Do Kim
Stock Analyst at Piper Sandler
(2.04)
# 3,067
Out of 5,072 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $82.73 | -23.85% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $35.41 | +29.91% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $433.61 | -31.74% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $125.84 | -11.00% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $17.56 | +395.44% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $1.73 | +1,233.33% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $50.49 | -60.39% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $10.00 | +330.00% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $44.17 | -27.55% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $3.73 | +489.81% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $44.03 | -56.85% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $8.03 | +99.25% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $451.23 | -59.00% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $4.18 | +21,431.10% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $71.40 | -50.98% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.14 | +1,654.39% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $82.73
Upside: -23.85%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $35.41
Upside: +29.91%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $433.61
Upside: -31.74%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $125.84
Upside: -11.00%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $17.56
Upside: +395.44%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $1.73
Upside: +1,233.33%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $50.49
Upside: -60.39%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $10.00
Upside: +330.00%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $44.17
Upside: -27.55%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $3.73
Upside: +489.81%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $44.03
Upside: -56.85%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $8.03
Upside: +99.25%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $451.23
Upside: -59.00%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $4.18
Upside: +21,431.10%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $71.40
Upside: -50.98%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.14
Upside: +1,654.39%